Cited 30 times in
Hepatocellular Carcinoma Risk Steadily Persists Over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김범경 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 이혜원 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2020-06-17T00:47:27Z | - |
dc.date.available | 2020-06-17T00:47:27Z | - |
dc.date.issued | 2020-01 | - |
dc.identifier.issn | 1055-9965 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/176124 | - |
dc.description.abstract | Background: Long-term antiviral therapy (AVT) for chronic hepatitis B (CHB) reduces the risk of hepatocellular carcinoma (HCC). We assessed the temporal trends in the incidence of HCC over time during long-term AVT among Asian patients with CHB. Methods: Patients with CHB receiving entecavir/tenofovir (ETV/TDF) as a first-line antiviral were recruited from four academic hospitals in the Republic of Korea. We compared the incidence of HCC during and after the first 5 years of ETV/TDF treatment. Results: Among 3,156 patients, the median age was 49.6 years and males predominated (62.4%). During the follow-up, 9.0% developed HCC. The annual incidence of HCC per 100 person-years during the first 5 years (n = 1,671) and after the first 5 years (n = 1,485) was statistically similar (1.93% vs. 2.27%, P = 0.347). When the study population was stratified according to HCC prediction model, that is, modified PAGE-B score, the annual incidence of HCC was 0.11% versus 0.39% in the low-risk group (<8 points), 1.26% versus 1.82% in the intermediate-risk group (9-12 points), and 4.63% versus 5.24% in the high-risk group (≥13 points; all P > 0.05). A Poisson regression analysis indicated that the duration of AVT did not significantly affect the overall trend of the incidence of HCC (adjusted annual incidence rate ratio = 0.85; 95% confidence interval, 0.66-1.11; P = 0.232). Conclusions: Despite long-term AVT, the risk of HCC steadily persists over time among patients with CHB in the Republic of Korea, in whom HBV genotype C2 predominates. Impact: Careful HCC surveillance is still essential. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | American Association for Cancer Research | - |
dc.relation.isPartOf | CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Hepatocellular Carcinoma Risk Steadily Persists Over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.contributor.googleauthor | Yeon Seok Seo | - |
dc.contributor.googleauthor | Han Ah Lee | - |
dc.contributor.googleauthor | Mi Na Kim | - |
dc.contributor.googleauthor | Eun Ju Lee | - |
dc.contributor.googleauthor | Hye Jung Shin | - |
dc.contributor.googleauthor | Yu Rim Lee | - |
dc.contributor.googleauthor | Hye Won Lee | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.contributor.googleauthor | Soon Ho Um | - |
dc.contributor.googleauthor | Won Young Tak | - |
dc.contributor.googleauthor | Young Oh Kweon | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Soo Young Park | - |
dc.identifier.doi | 10.1158/1055-9965.EPI-19-0614 | - |
dc.contributor.localId | A00385 | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A03318 | - |
dc.contributor.localId | A04268 | - |
dc.relation.journalcode | J00441 | - |
dc.identifier.eissn | 1538-7755 | - |
dc.identifier.pmid | 31988073 | - |
dc.identifier.url | https://cebp.aacrjournals.org/content/29/4/832.long | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | 김도영 | - |
dc.contributor.affiliatedAuthor | 김범경 | - |
dc.contributor.affiliatedAuthor | 김승업 | - |
dc.contributor.affiliatedAuthor | 박준용 | - |
dc.contributor.affiliatedAuthor | 안상훈 | - |
dc.contributor.affiliatedAuthor | 이혜원 | - |
dc.contributor.affiliatedAuthor | 한광협 | - |
dc.citation.volume | 29 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 832 | - |
dc.citation.endPage | 837 | - |
dc.identifier.bibliographicCitation | CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, Vol.29(4) : 832-837, 2020-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.